Jazz Pharmaceuticals reports Q1 adjusted EPS $1.68 vs. $2.63 last year

Reports Q1 revenue $898M, consensus $983.75M. “In the first quarter of 2025, our focus on commercial execution resulted in total revenues of $898 million, led by the strong performance of Xywav and Epidiolex. In addition, our team continues to receive positive feedback from healthcare providers on the launch of Ziihera in its first approved indication of 2L HER2+ BTC. We are affirming our 2025 total revenue guidance range of $4.15 – $4.40 billion, reflecting our confidence in our commercial portfolio delivering top-line growth this year,” said Bruce Cozadd, chairman and chief executive officer, Jazz Pharmaceuticals (JAZZ). “We continue to make meaningful progress across our pipeline. We are pleased to report that we have submitted a supplemental New Drug Application for Zepzelca for maintenance therapy in first-line extensive-stage small cell lung cancer. In addition, we recently completed the acquisition of Chimerix, adding a near-term commercial opportunity to our late-stage pipeline that addresses a significant unmet need for patients with H3 K27M-mutant diffuse glioma, a rare, high-grade brain tumor that most commonly affects children and young adults. We also advanced multiple trials across our zanidatamab development program and expect top-line data readout from the HERIZON-GEA-01 trial in 1L GEA in the second half of 2025.”